Introduction: A Paradigm Shift in Urological Care
Procept BioRobotics, a leader in surgical robotics for urological conditions, has marked a significant milestone in its clinical development strategy. The company has officially received a second Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), paving the way for a groundbreaking expansion of its WATER IV clinical trial program. This development underscores the growing clinical interest in Aquablation therapy—a heat-free, robotic-assisted surgical procedure—as a viable, quality-of-life-preserving alternative to traditional prostate cancer interventions.
As the medical community shifts toward personalized oncology, Procept’s dual-track approach to the WATER IV study represents a ambitious commitment to long-term clinical evidence, aiming to validate Aquablation not only as a replacement for radical surgery but as a proactive intervention for patients currently relegated to "active surveillance."
Main Facts: The WATER IV Program Architecture
The core of this announcement lies in the structural expansion of the WATER IV trials. Aquablation therapy is uniquely positioned in the urological market due to its use of a robotic, image-guided waterjet to precisely remove prostate tissue without the thermal damage associated with traditional laser or heat-based ablative therapies.
The Original WATER IV Protocol
The first arm of the WATER IV study has successfully reached its full enrollment of 280 patients. This randomized, controlled trial is designed to provide a head-to-head comparison between Aquablation and radical prostatectomy—the long-standing "gold standard" surgical treatment for prostate cancer. By comparing these two modalities, Procept aims to demonstrate that Aquablation provides comparable oncological outcomes while potentially offering a superior profile regarding postoperative urinary and sexual function. Procept expects to release the primary endpoint results for this cohort in 2027.
The New WATER IV AS Protocol
The newly approved second protocol, dubbed "WATER IV AS," shifts the focus to the "Active Surveillance" (AS) population. AS is a standard management strategy for low-to-intermediate risk prostate cancer (Grade Group 1 and 2), involving regular monitoring rather than immediate surgery or radiation. The new study will enroll up to 333 patients globally to evaluate whether an earlier, minimally invasive intervention with Aquablation can prevent disease progression while preserving patient quality of life.
Chronology of Clinical Advancement
The journey toward this latest regulatory achievement is part of a broader, multi-year strategic roadmap established by Procept BioRobotics.
- Pre-2024: Development and clinical validation of the Hydros Robotic System, establishing the foundation for precise, image-guided waterjet ablation.
- August 2024: A pivotal moment for the company as the FDA issued 510(k) clearance for the Hydros Robotic System. This regulatory win solidified the commercial viability of the platform and set the stage for the current clinical expansion.
- Late 2024–Early 2026: Steady recruitment for the initial WATER IV protocol, culminating in the recent announcement of full enrollment of 280 patients.
- May 2026: FDA approval of the second IDE, allowing the launch of the WATER IV AS trial.
- 2027 (Anticipated): Public disclosure of primary endpoint results from the first WATER IV cohort.
- Long-Term Horizon: The WATER IV AS trial is structured for a ten-year longitudinal follow-up, representing one of the most comprehensive early-stage evaluation protocols in the history of prostate cancer treatment.
Supporting Data: Why Long-Term Evaluation Matters
The significance of the WATER IV trials cannot be overstated. In the current landscape of prostate cancer care, the "trade-off" between cancer control and side effects (such as incontinence and erectile dysfunction) remains a primary concern for patients.
Defining the Methodology
Both arms of the WATER IV trials utilize a rigorous longitudinal monitoring framework. Key milestones in the WATER IV AS study include:
- Year 1: Mandatory biopsy to determine immediate post-intervention success.
- Year 3: Comprehensive magnetic resonance imaging (MRI) evaluation of the entire prostate to assess tissue changes and ensure no occult disease progression.
- Decadal Follow-up: A 10-year monitoring window for disease control, sexual function, and urinary health.
According to data released by the company, no other prostate cancer therapy has undergone this level of granular, long-term, early-stage evaluation. By standardizing these metrics across hundreds of patients, Procept intends to move beyond anecdotal success to create a robust dataset that could redefine clinical guidelines.
Official Responses: Leadership Perspectives
The leadership at Procept BioRobotics views these developments as a validation of their vision to improve the standard of care. Larry Wood, President and CEO of Procept BioRobotics, emphasized that the enthusiasm for the trial is shared by both the medical community and the patient population.
"We are excited to complete enrollment in the first randomized WATER IV protocol, reflecting strong interest from physician investigators, as well as patients in evaluating Aquablation as a new approach to prostate cancer treatment," Wood stated.
Addressing the significance of the new AS protocol, he added: "The IDE approval for the additional randomized WATER IV protocol enables us to evaluate whether earlier intervention with Aquablation may offer men on active surveillance a quality-of-life-preserving treatment option rather than waiting for the disease to progress."
This sentiment highlights a crucial shift in medical philosophy: moving from "watchful waiting" to "intervention-led prevention" without the immediate jump to aggressive, high-morbidity surgery.
Implications: The Future of Prostate Cancer Management
The implications of the WATER IV program extend far beyond the operating room.
1. Market Disruption
If the 2027 results confirm that Aquablation provides non-inferior oncological outcomes to radical prostatectomy, it could fundamentally alter the market share of robotic surgical platforms. Surgeons currently reliant on traditional techniques may find a compelling reason to integrate Hydros systems into their practices to offer patients a less invasive option.
2. Changing the Patient Experience
For men diagnosed with low-grade prostate cancer, the psychological burden of "active surveillance" is well-documented. Many patients experience anxiety regarding the possibility of their cancer "upgrading" while under observation. A safe, proven, and minimally invasive intervention could provide these men with peace of mind, potentially reducing the rates of psychological distress associated with prostate cancer management.
3. Setting a New Gold Standard for Evidence
By committing to a ten-year follow-up, Procept is effectively raising the bar for the medical device industry. Future entrants into the prostate cancer therapy market will likely face pressure to provide similar longitudinal data. This increased transparency will ultimately benefit the patient, as clinicians will have more definitive evidence to guide their treatment recommendations.
4. Economic Considerations
While the initial cost of robotic technology is high, the potential for reduced long-term side effects—such as the avoidance of follow-up treatments for urinary incontinence—could lead to significant cost-of-care savings for healthcare systems. The data collected from the WATER IV trials will likely be scrutinized by health insurance providers and government payers to determine the long-term value proposition of Aquablation.
Conclusion: A Milestone for Urology
The trajectory of Procept BioRobotics serves as a microcosm of the broader evolution in modern medicine: the marriage of advanced robotics, precise imaging, and long-term data collection. With the WATER IV study fully enrolled and the WATER IV AS trial now authorized, the company is well-positioned to lead a transition in how prostate cancer is viewed and managed.
As the industry looks toward 2027 and beyond, the data generated from these trials will be closely watched by oncologists, urologists, and health policy experts alike. Whether Aquablation becomes the definitive alternative to radical prostatectomy or a vital new tool for early-stage intervention, Procept’s commitment to evidence-based innovation has set a clear path for the future of the field. For the millions of men navigating a prostate cancer diagnosis, this represents more than just a new medical device—it represents the potential for a life-changing improvement in both survival and daily quality of life.
About the Author
